This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://linked.opendata.cz/resource/drugbank/drug/DB01270/identifier/national-drug-code-directory/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/mesh/concept/
n18http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/dosage/
n16http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB01270/identifier/pharmgkb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01270/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n22http://www.rxlist.com/cgi/generic/
n17http://linked.opendata.cz/resource/drugbank/patent/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01270/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01270/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01270
rdf:type
n3:Drug
n3:description
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name Lucentis®. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
n3:dosage
n12:271B61A8-363D-11E5-9242-09173F13E4C5 n12:271B61A6-363D-11E5-9242-09173F13E4C5 n12:271B61A7-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# IGMT "Link":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1CZ8&Part=Chain # Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA: Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007 Nov-Dec;27(9):1260-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18046235 # Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V: Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15671306 # Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA: Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007 Nov-Dec;27(9):1260-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18046235 # Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007 Dec;114(12):2179-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18054637 # Kourlas H, Abrams P: Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007 Sep;29(9):1850-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18035187
n3:group
approved
n3:halfLife
Approximately 9 days.
n3:indication
For the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
owl:sameAs
n16:DB01270 n25:DB01270
dcterms:title
Ranibizumab
adms:identifier
n8:Ranibizumab n9:PA164746012 n13:DB01270 n14:D05697 n21:50242-080-01
n3:mechanismOfAction
Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF<sub>110</sub>. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
n3:packager
n18:271B61A4-363D-11E5-9242-09173F13E4C5 n18:271B61A3-363D-11E5-9242-09173F13E4C5
n3:patent
n17:2286330
n3:synonym
rhuFab V2
n3:toxicity
The most common toxic effects to the eye are eye pain, vitreous floaters, increased intraocular pressure, conjunctival hemorrhage, intraocular inflammation, and foreign body sensation. Also arterial thromboembolic events have occurred in patients.
n3:volumeOfDistribution
Volume of distribution is insignificant.
n3:foodInteraction
No food effects found.
n3:proteinBinding
Plasma protein binding is insignificant.
n10:hasConcept
n11:M0481787
foaf:page
n6:ranibizumab.html n22:lucentis.htm
n3:Molecular-Formula
n4:271B61AD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B61AC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B61A9-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n24:S01LA04
n3:absorption
After monthly intravitreal injections, maximum serum concentrations are minimal around 0.3 ng/mL to 2.36 ng/mL.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
347396-82-1
n3:category
n3:clearance
Clearance was not quantified.
n3:containedIn
n19:271B61A5-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B61AB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B61AA-363D-11E5-9242-09173F13E4C5